Drug interactions between Miradon and Xarelto
| Results for the following 2 drugs: |
|---|
| Miradon (anisindione) |
| Xarelto (rivaroxaban) |
Interactions between your selected drugs
anisindione ↔ rivaroxaban
Applies to:Miradon (anisindione) and Xarelto (rivaroxaban)
GENERALLY AVOID: The concomitant use of rivaroxaban with other anticoagulants may increase the risk of bleeding. In addition, in patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during antithrombotic therapy may be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term neurological injury or permanent paralysis. In a drug interaction study, an additive effect on antifactor Xa activity was observed when single doses of enoxaparin (40 mg subcutaneous) and rivaroxaban (10 mg) were given concurrently. Likewise, an additive effect on factor Xa inhibition and prothrombin time occurred when single doses of warfarin (15 mg) and rivaroxaban (5 mg) were given together. The safety of long-term coadministration of these drugs has not been studied.
MANAGEMENT: Due to increased bleeding risk, the use of rivaroxaban in combination with other anticoagulants should generally be avoided except during therapeutic transition periods where patients should be observed closely. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). In patients undergoing neuraxial intervention, the use of rivaroxaban should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
